FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

In this episode, we discuss:

• The FDA advisory committee process and its implications for drug approvals
• Functional unblinding and expectancy effects in psychedelic clinical trials
• Potential impacts on the broader psychedelic medicine industry
• The future of psychedelic-assisted psychotherapy protocols
• Neuroplastogen development and non-hallucinogenic approaches
• Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis,  Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank